[go: up one dir, main page]

AU2002317377A1 - Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer - Google Patents

Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer

Info

Publication number
AU2002317377A1
AU2002317377A1 AU2002317377A AU2002317377A AU2002317377A1 AU 2002317377 A1 AU2002317377 A1 AU 2002317377A1 AU 2002317377 A AU2002317377 A AU 2002317377A AU 2002317377 A AU2002317377 A AU 2002317377A AU 2002317377 A1 AU2002317377 A1 AU 2002317377A1
Authority
AU
Australia
Prior art keywords
apurinic
biphenyl
treat cancer
apyrimidinic site
endonuclease inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002317377A
Inventor
Timothy Robin Hammonds
Ian David Hickson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of AU2002317377A1 publication Critical patent/AU2002317377A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002317377A 2001-07-20 2002-07-22 Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer Abandoned AU2002317377A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30667901P 2001-07-20 2001-07-20
US60/306,679 2001-07-20
PCT/GB2002/003342 WO2003007955A2 (en) 2001-07-20 2002-07-22 Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer

Publications (1)

Publication Number Publication Date
AU2002317377A1 true AU2002317377A1 (en) 2003-03-03

Family

ID=23186355

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002317377A Abandoned AU2002317377A1 (en) 2001-07-20 2002-07-22 Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer

Country Status (2)

Country Link
AU (1) AU2002317377A1 (en)
WO (1) WO2003007955A2 (en)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004525118A (en) * 2001-01-22 2004-08-19 アルパイダ　アーゲー New hydrazones
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
JP2005524672A (en) 2002-03-09 2005-08-18 アストラゼネカ アクチボラグ Imidazolyl-substituted pyrimidine derivatives having CDK inhibitory activity
MXPA05012281A (en) 2003-05-14 2006-05-19 Torreypines Therapeutics Inc Compouds and uses thereof in modulating amyloid beta.
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
WO2004108139A2 (en) * 2003-06-06 2004-12-16 Arexis Ab Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer
CA2528785A1 (en) * 2003-06-20 2005-01-06 Matthias Heinrich Nettekoven 2-amidobenzothiazoles as cb1 receptor inverse agonists
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
WO2005113511A1 (en) * 2004-05-12 2005-12-01 Bristol-Myers Squibb Company Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
AU2005260495B2 (en) * 2004-07-02 2009-04-30 Sankyo Company, Limited Urea derivative
SG155188A1 (en) * 2004-07-30 2009-09-30 Exelixis Inc Pyrrole derivatives as pharmaceutical agents
KR100784337B1 (en) * 2004-11-12 2007-12-13 한국생명공학연구원 Novel O-acyl oxime derivative, preparation method thereof and pharmaceutical composition for the prevention and treatment of cardiovascular diseases comprising the active ingredient
DE602006020327D1 (en) 2005-01-19 2011-04-07 Bristol Myers Squibb Co 2-PHENOXY-N- (1,3,4-THIADIZOL-2-YL) PYRIDINE-3-AMINDER INHIBITOR FOR THE TREATMENT OF THROMBOEMBOLIC ILLNESSES
WO2007002584A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7700620B2 (en) 2005-06-27 2010-04-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
DE602006021306D1 (en) 2005-06-27 2011-05-26 Bristol Myers Squibb Co
SG164368A1 (en) 2005-07-18 2010-09-29 Bipar Sciences Inc Treatment of cancer
AU2007215247B2 (en) 2006-02-10 2012-12-13 Transtech Pharma, Llc Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors
CA2662517A1 (en) 2006-09-05 2008-03-13 Jerome Moore Treatment of cancer
RS52349B (en) 2006-09-26 2012-12-31 Celgene Corporation 5-SUBSTITUTED HINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP5442449B2 (en) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド New compounds
HRP20150642T1 (en) 2006-12-22 2015-08-14 Astex Therapeutics Limited BIKE HETEROCYCLIC SUBSTANCES AS FGFR INHIBITORS
CA2674075C (en) 2006-12-29 2012-10-30 Charles P. Theuer Antifolate agent combinations in the treatment of cancer
EP1972624A1 (en) * 2007-03-23 2008-09-24 Clariant International Ltd. Benzoxazinones and their use as ultraviolet light absorbers
WO2009041972A1 (en) * 2007-09-27 2009-04-02 University Of Notre Dame Du Lac Antibacterial compounds and methods of using same
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
RU2480211C2 (en) 2007-11-12 2013-04-27 Байпар Сайенсиз, Инк. Method of treating breast cancer with compound of 4-iodine-3-nitrobenzamine in combination with anticancer agents
WO2009082398A1 (en) 2007-12-21 2009-07-02 University Of Notre Dame Du Lac Antibacterial compounds and methods of using same
RU2474575C2 (en) 2008-03-26 2013-02-10 Дайити Санкио Компани, Лимитед Novel tetrahydroisoquinoline derivative, pharmaceutical composition based thereon, use thereof and method of treating and/or preventing disease
KR101257158B1 (en) 2008-05-23 2013-04-23 노파르티스 아게 Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
CA2732437C (en) 2008-08-01 2017-11-21 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
EP2358683B1 (en) 2008-11-06 2015-04-01 VentiRx Pharmaceuticals, Inc. Methods of synthesis of benzazepine derivatives
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
HUE032626T2 (en) 2009-08-18 2017-10-30 Ventirx Pharmaceuticals Inc Substituted benzoazepines as toll-like receptor modulators
EP2467380B1 (en) 2009-08-18 2016-11-30 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
ES2803556T3 (en) 2010-06-01 2021-01-27 Summit Oxford Ltd Compounds for the treatment of diseases associated with clostridium difficile
AU2011265047B2 (en) 2010-06-07 2014-10-23 Novomedix, Llc Furanyl compounds and the use thereof
UY33337A (en) 2010-10-18 2011-10-31 Respivert Ltd SUBSTITUTED DERIVATIVES OF 1H-PIRAZOL [3,4-d] PYRIMIDINE AS INHIBITORS OF PHOSFOINOSITIDE 3-KINASES
GB201020397D0 (en) * 2010-12-02 2011-01-12 Univ Nottingham Compounds
CA2829570C (en) 2011-03-11 2019-05-07 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
CN104066729A (en) 2011-08-15 2014-09-24 英特穆恩公司 Lysophosphatidic acid receptor antagonists
CN106957282B (en) 2011-12-21 2019-08-30 诺维拉治疗公司 Viral hepatitis type b antivirotic
TWI586378B (en) 2012-03-13 2017-06-11 瑞斯比維特有限公司 Novel pharmaceutical formulations
AR092270A1 (en) 2012-08-28 2015-04-08 Janssen R&D Ireland SULFAMOILARILAMIDAS AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
EP2892887B1 (en) 2012-09-04 2020-07-15 Celgene Corporation Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
CN103664919B (en) * 2012-09-26 2016-02-10 李超 A kind ofly can be used for the compound preparing chemotherapeutics
EP2925718B1 (en) * 2012-11-30 2018-08-01 Novomedix, LLC Substituted biaryl sulfonamides and the use thereof
US9745328B2 (en) 2013-02-04 2017-08-29 Janssen Pharmaceutica Nv Flap modulators
TWI644899B (en) 2013-02-04 2018-12-21 健生藥品公司 Flap modulators
ES2628953T3 (en) 2013-02-28 2017-08-04 Janssen Sciences Ireland Uc Sulfamoylarylamides and their use as medicines for the treatment of hepatitis B
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
JO3279B1 (en) 2013-03-15 2018-09-16 Respivert Ltd 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors
AR095353A1 (en) 2013-03-15 2015-10-07 Respivert Ltd COMPOUND
MX353412B (en) 2013-04-03 2018-01-10 Janssen Sciences Ireland Uc N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b.
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulfamoyl pyrolamide derivatives and their use as medicines to treat hepatitis B
PL3024819T3 (en) 2013-07-25 2018-08-31 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
DK3054936T5 (en) 2013-10-10 2024-03-18 Eastern Virginia Medical School 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS
SG11201602748XA (en) 2013-10-23 2016-05-30 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (en) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Combination therapy for treatment of hbv infections
ES2705401T3 (en) 2014-02-06 2019-03-25 Janssen Sciences Ireland Uc Derivatives of sulfamoylpyrrollamide and its use as medicines for the treatment of Hepatitis B
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
US10662164B2 (en) 2014-09-25 2020-05-26 University Of Notre Dame Du Lac Non-beta lactam antibiotics
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
EP3271019A1 (en) 2015-03-19 2018-01-24 Novira Therapeutics Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JP6845231B2 (en) 2015-09-29 2021-03-17 ノヴィラ・セラピューティクス・インコーポレイテッド Crystalline form of hepatitis B antiviral drug
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
KR20180129943A (en) 2016-04-15 2018-12-05 노비라 테라퓨틱스, 인코포레이티드 Formulations and methods involving capsid assembly inhibitors
US11168062B2 (en) 2016-09-12 2021-11-09 University Of Notre Dame Du Lac Compounds for the treatment of Clostridium difficile infection
CN111065383A (en) 2017-07-11 2020-04-24 沃泰克斯药物股份有限公司 Carboxamides as Sodium Channel Modulators
KR102717600B1 (en) 2017-10-06 2024-10-15 포르마 세라퓨틱스 인크. Inhibition of ubiquitin-specific peptidase 30
WO2020039094A1 (en) * 2018-08-24 2020-02-27 Xeniopro GmbH Phenoxy(hetero)aryl ethers of antiproliferative activity
EP3765011A1 (en) 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
CN112513036B (en) 2018-05-17 2024-05-24 福马治疗有限公司 Fused bicyclic compounds as inhibitors of ubiquitin-specific peptidase 30
ES2945834T3 (en) 2018-10-05 2023-07-07 Forma Therapeutics Inc Fused pyrrolines that act as inhibitors of ubiquitin-specific protease 30 (USP30)
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
MA55020A (en) 2019-02-22 2021-12-29 Janssen Sciences Ireland Unlimited Co AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR DISEASES INDUCED BY HEPATITIS B VIRUS
CN109820850A (en) * 2019-04-10 2019-05-31 广西中医药大学 Application of α-triplethiophene in the preparation of drugs for the treatment of prostate cancer
AR119732A1 (en) 2019-05-06 2022-01-05 Janssen Sciences Ireland Unlimited Co AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES
US12460207B2 (en) 2021-03-16 2025-11-04 The Cleveland Clinic Foundation Inhibiting APE2 expression in a subject treated with a drug agent that causes increased APE2 expression
KR20220157089A (en) * 2021-05-20 2022-11-29 연세대학교 산학협력단 A composition for preventing, alleviating or treating cancer
CN114106586B (en) * 2021-12-13 2022-11-01 江南大学 Schiff base disperse dyes with photochromic and fluorescent functions, preparation method and application
TW202448435A (en) * 2023-02-28 2024-12-16 美商賽堤爾醫療公司 Substituted thiadiazolyl compounds
WO2025196064A1 (en) * 2024-03-20 2025-09-25 Thorne Limited Swap70 inhibitors for use in the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4183931A (en) * 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
CA2135160A1 (en) * 1992-05-08 1993-11-25 Masatoshi Inai Indole derivative
JPH08503450A (en) * 1992-08-06 1996-04-16 ワーナー−ランバート・コンパニー 2-Thioindole (selenoindole) and related disulfides (selenides) that inhibit protein tyrosine kinases and have antitumor properties
US5703130A (en) * 1995-06-07 1997-12-30 Institute Of Materia Medica, An Institute Of The Chinese Academy Of Medical Sciences Chalcone retinoids and methods of use of same
JPH11514651A (en) * 1995-10-31 1999-12-14 メルク エンド カンパニー インコーポレーテッド Substituted pyridylpyrroles, compositions containing said compounds and methods of use
EP0923738A1 (en) * 1996-06-11 1999-06-23 Advanced Research &amp; Technology Institute Methods and compositions for the use of apurinic/apyrimidinic endonucleases
US6218539B1 (en) * 1996-06-27 2001-04-17 Smithkline Beecham Corporation IL-8 receptor antagonists
FR2762841B1 (en) * 1997-04-30 1999-07-02 Jouveinal Inst Rech DIAZEPINO-INDOLONES INHIBITING PHOSPHODIESTERASES IV
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
CN1213022C (en) * 1997-12-22 2005-08-03 拜尔有限公司 Inhibition of raf kinase using symmerical and unsymmerical substituted diphenyl ureas
DK1047418T3 (en) * 1997-12-22 2005-11-21 Bayer Pharmaceuticals Corp Inhibition of raf kinase by substituted heterocyclic ureas
WO1999048878A1 (en) * 1998-03-24 1999-09-30 Novo Nordisk A/S Heterocyclic compounds regulating clotting
EP1073643B1 (en) * 1998-04-23 2004-12-29 Dr. Reddy's Laboratories Ltd. New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
JPH11322611A (en) * 1998-05-14 1999-11-24 Sankyo Co Ltd Antiviral agent
US6337332B1 (en) * 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
US6187779B1 (en) * 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
WO2002026718A2 (en) * 2000-09-29 2002-04-04 Millennium Pharmaceutical, Inc. Bicyclic pyrimidin-4-one based inhibitors of factor xa

Also Published As

Publication number Publication date
WO2003007955A2 (en) 2003-01-30
WO2003007955A3 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
AU2002317377A1 (en) Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
AU2002361846A1 (en) Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2002364211A1 (en) Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2002367466A1 (en) Amplification of nucleic acid fragments using nicking agents
AU2001266068A1 (en) Treatment of mineral substrates
AU2003256847A1 (en) Method of treating cancer
AU2003278088A1 (en) Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
IL157652A (en) Metalloproteinase inhibitors, compositions comprising them and uses thereof for the preparation of medicaments for treating diseases or conditions mediated by metalloproteinase enzymes
ZA200304893B (en) Ether derivatives useful as inhibitors of PDE4 isozymes.
AU2002328952A1 (en) Irinotecan for treatment of cancer
AU2002340168A1 (en) Treatment of prostate cancer by inhibitors of ncam2
AU2003225535A1 (en) Methods and compositions for treating cancer
AU2002367172A1 (en) 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2003232848A1 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
AU2003295336A1 (en) Use of etodoclac to treat hyperplasia
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
AU2003260945A1 (en) Methods of use for thermostable rna ligases
AU2002340129A1 (en) Self-administered two-handled probe for treating prostatitis
AU2002307100A1 (en) Use of tumor necrosis factor inhibitors to treat cardiovascular disease
AU2001253836A1 (en) Method of treating cancer
AU2003280558A1 (en) Method for treatment of cancer
AU2001241779A1 (en) Method of treatment of prostate cancer
WO2004060878A3 (en) Inhibitors of phosphatases
AU2003248710A1 (en) Methods of use for tripeptidyl peptidase ii inhibitors as anticancer agents

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase